Tens of thousands of surgical procedures are performed every year in the UK to resolve symptoms of anal bleeding and prolapse caused by haemorrhoids.
1 A steady stream of novel therapeutic approaches may promise more convenient, comfortable, and ultimately eff ective treatment for this common complaint, but innovation is generally associated with increased cost and complexity compared with standard outpatient rubber band ligation (RBL). New surgical devices require systematic evaluation to support development of eff ective patient pathways that make effi cient use of precious health-care resources. 2 Haemorrhoidal artery ligation (HAL) uses Doppler equipped proctoscopy to pinpoint branches of the haemorrhoidal artery that supply blood to haemorrhoids. These feeding vessels are sutured to inhibit further bleeding, while a second stitch fi rmly fi xes the pile within the anal canal to prevent prolapse. Advocates of HAL suggest that it is much more eff ective than standard RBL as a fi rst-line treatment of haemorrhoids, justifying the increased cost and use of general or spinal anaesthesia. 3, 4 To our knowledge, no randomised controlled trials have compared HAL with RBL until now.
In The Lancet, Steven Brown and colleagues 5 present HubBLe, a randomised, non-blinded, multicentre, phase 3 study comparing standard RBL versus HAL for fi rst-line or selected second-line treatment of symptomatic haemorrhoids that prolapse and bleed following defecation (ie, grades II and III). This is a clinically relevant patient population that constitutes a large proportion of the surgical workload. Individuals with a history of haemorrhoid surgery or repeated outpatient treatments in the preceding 3 years were excluded.
Recurrence of haemorrhoids or haemorrhoidal symptoms at 12 months constituted the primary endpoint. This composite assessment was based on the presence of any one of the following: (1) patients reporting "unchanged or worse" symptoms, rather than "cured or improved", during a telephone assessment, (2) further therapy being administered, or (3) symptoms suggestive of haemorrhoids being recorded in the medical notes and verifi ed by two investigators blinded to treatment allocation. The study was powered to detect a 50% reduction in haemorrhoid recurrence at 12 months, from 30% with RBL to 15% with HAL. Secondary endpoints assessed at 6 weeks and 12 months included symptom severity score, pain score, surgical complications, further treatment, and health state utility using EQ-5D.
Between September, 2012, and May, 2014, 372 patients entered the study, of whom 340 received treatment. Assessment of the primary outcome was possible in 337 patients using 256 patient-reported outcomes, 236 GP forms, and 337 consultant reports. Groups were generally well balanced with marginally more severe haemorrhoids allocated to HAL, and more previously treated patients allocated to RBL.
The major fi nding of this study was that haemorrhoid recurrence at 12 months was signifi cantly lower following HAL (48 [30%] of 161 patients) than following RBL (87 [49%] of 176 patients). Actual recurrence rates were much higher than predicted, possibly refl ecting use of a sensitive patient-reported outcome. Further analysis of the composite primary endpoint revealed that this treatment eff ect was accounted for by patients receiving multiple RBL who were classifi ed as having recurred. In our opinion, patients frequently require a course of RBL to achieve optimal symptom control, and the investigators might have inadvertently designated residual haemorrhoids as recurrences. Evaluation of patient-reported dissatisfaction at 12 months revealed no diff erence between RBL and HAL (29%), suggesting that multiple RBL had similar eff ectiveness than did HAL from the patients' perspectives.
Surprisingly, HAL was associated with increased pain and a persistent reduction in EQ-5D compared with RBL, contrary to the widely held belief that it represents a painless approach to management of haemorrhoids. 6 Costs were also higher.
The HubBLe trial will undoubtedly change practice within the UK and other health-care systems with fi nite resources. It is unique in directly comparing fi rst-line haemorrhoidal interventions considered of most utility by colorectal surgeons and most acceptable by patients. 7, 8 This study has provided valuable information about the natural history of haemorrhoidal symptoms following treatment, and established a "course" of banding as a real, safe, and more cost-eff ective means of alleviating prolapse and bleeding in the majority of patients. The National Institute for Health and Care Excellence (NICE) will probably wish to update their recommendations on HAL. Aspirin is considered an aff ordable and widely available, if only modestly eff ective, thromboprophylactic for secondary stroke prevention. The two large randomised controlled trials of aspirin in acute ischaemic stroke reported that aspirin reduced the odds of early recurrent stroke at 2-4 weeks by about 12% (odds ratio [OR] 0·88, 95% CI 0·79-0·97) and the odds of death or dependency at the end of follow-up by about 5% (OR 0·95, 0·91-0·99).
1 The ten trials of aspirin for long-term secondary prevention in patients with previous transient ischaemic attack (TIA) or ischaemic stroke reported that aspirin reduced the risk of any recurrent stroke over 3 years by about 17% (relative risk [RR] 0·83, 95% CI 0·72-0·96). 2 However, non-randomised observational studies have suggested that urgent medical treatments, including aspirin, in acute TIA and mild ischaemic stroke reduce the risk of recurrent stroke by up to 80%. 3 In The Lancet, Peter Rothwell and colleagues 4 report fi ndings from an analysis of the individual patient data from all randomised controlled trials of aspirin after ischaemic stroke or TIA, giving fresh insights into the eff ect of aspirin on the timing and severity of recurrent stroke and challenging our understanding of the role of aspirin in secondary stroke prevention.
Rothwell and colleagues found that in the three trials of aspirin versus control in acute ischaemic stroke (n=40 531), the overall eff ect of aspirin was indeed modest. However, there was signifi cant heterogeneity according to baseline stroke severity (p het =0·014). Aspirin appeared far more eff ective in reducing the 14 day risk of recurrent ischaemic stroke in patients with mild (OR 0·51, 95% CI 0·34-0·75) and moderate (0·65, 0·44-0·98) neurological damage after stroke, than for those with severe defi cits (OR 1·10, 0·77-1·58). Also, the reduction in recurrent stroke among patients with mild and moderate stroke was as great as half to two-thirds within the fi rst 2-6 days.
Moreover, among the 12 trials of secondary prevention of stroke in 15 778 patients with TIA or ischaemic
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The HubBLe study can help establish realistic patient expectations and provide a framework for counselling patients. This study has been a trend setter in selecting patient-reported outcomes as the primary endpoint. In context, patient-reported outcomes are now widely used, although this development is recent. 10 Use of a patientcentric qualitative endpoint is underpinned by the highquality health economics model applied in HubBLe.
The role of HAL, which has become widely accepted as a safe intervention for grade II-III haemorrhoids, will need re-evaluation. However, HAL might fi nd a niche role as second-line treatment for patients who relapse following a course of RBL and do not wish to have excisional haemorrhoidectomy.
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